Peptide-Based Approach to Inhibition of the Multidrug Resistance Efflux Pump AcrB
Joshua A Jesin1,2, Tracy A Stone1,2, Chloe J Mitchell1,2
1Division of Molecular Medicine, Research Institute, Hospital for Sick Children, Toronto M5G 0A4, Ontario, Canada.
Abstract:
Clinically relevant multidrug-resistant bacteria often arise due to overproduction of membrane-embedded efflux proteins that are capable of pumping antibiotics out of the bacterial cell before the drugs can exert their intended toxic effect. The Escherichia coli membrane protein AcrB is the archetypal protein utilized for bacterial efflux study because it can extrude a diverse range of antibiotic substrates and has close homologues in many Gram-negative pathogens. Three AcrB subunits, each of which contains 12 transmembrane (TM) helices, are known to trimerize to form the minimal functional unit, stabilized noncovalently by helix-helix interactions between TM1 and TM8. To inhibit the efflux activity of AcrB, we have rationally designed synthetic peptides aimed at destabilizing the AcrB trimerization interface by outcompeting the subunit interaction sites within the membrane. Here we report that peptides mimicking TM1 or TM8, with flanking N-terminal peptoid tags, and C-terminal lysine tags that aid in directing the peptides to their membrane-embedded target, decrease the AcrB-mediated efflux of the fluorescent substrate Nile red and potentiate the effect of the antimicrobials chloramphenicol and ethidium bromide. To further characterize the motif encompassing the interaction between TM1 and TM8, we used Förster resonance energy transfer to demonstrate dimerization. Using the TM1 and TM8 peptides, in conjunction with several selected mutant peptides, we highlight residues that may increase the potency and specificity of the peptide drug candidates. In targeting membrane-embedded protein-protein interactions, this work represents a novel approach to AcrB inhibition and, more broadly, a potential route to a new category of efflux pump inhibitors.
Insights
Researchers designed synthetic peptides to disrupt the AcrB efflux pump in bacteria. These peptides successfully reduced antibiotic efflux and enhanced antimicrobial effectiveness, offering a novel strategy against multidrug resistance.
Area of Science:
- Microbiology
- Structural Biology
- Drug Discovery
Background:
- Multidrug resistance in bacteria is a significant clinical challenge, often driven by efflux pumps that expel antibiotics.
- The AcrB efflux pump in *Escherichia coli* is a key target due to its broad substrate range and prevalence in pathogens.
- AcrB functions as a trimer, stabilized by interactions between transmembrane helices TM1 and TM8.
Purpose of the Study:
- To design and evaluate synthetic peptides targeting the AcrB trimerization interface.
- To inhibit AcrB-mediated multidrug efflux and potentiate existing antibiotics.
- To explore a novel therapeutic strategy against bacterial efflux pumps.
Main Methods:
- Rational design of synthetic peptides mimicking TM1 and TM8 helices of AcrB.
- In vitro assays measuring Nile red efflux to assess AcrB activity.
- Förster resonance energy transfer (FRET) to study protein-protein interactions and dimerization.
- Testing peptide efficacy in potentiating antibiotics like chloramphenicol and ethidium bromide.
Main Results:
- Designed peptides successfully decreased AcrB-mediated efflux of Nile red.
- Peptides potentiated the activity of chloramphenicol and ethidium bromide, indicating enhanced drug efficacy.
- FRET analysis confirmed the role of TM1-TM8 interactions in AcrB dimerization.
- Mutant peptide analysis identified key residues for optimizing peptide potency and specificity.
Conclusions:
- Synthetic peptides targeting the AcrB trimerization interface represent a novel approach to inhibit efflux pumps.
- This strategy offers a potential new class of antibiotics to combat multidrug-resistant bacteria.
- Targeting membrane protein-protein interactions is a viable method for developing efflux pump inhibitors.
Related Concept Videos
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
ABC Transporters: Exporter
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Drug Elimination by Renal Route: Tubular Reabsorption


